WuXi Biologics signs lease for a clinical manufacturing facility in the US

9 Jun 2020

The deal represents the contract manufacturer's third US site.

WuXi Biologics, a global company with open-access technology platforms, has signed a 10-year lease for a clinical manufacturing facility (MFG18) in Cranbury, New Jersey.

WuXi Biologics signs lease for a clinical manufacturing facility in the US

The new clinical manufacturing facility will install in total 6000-L bioreactors, process development, quality control laboratories, along with supporting functions. The 66,000-sq. ft facility is expected to become operational in late 2020 and will bring in up to 100 jobs to the region.

This news follows WuXi Biologics' recent purchase of land to build a new 107,000-sq. ft clinical and commercial manufacturing facility in Worcester, Massachusetts, and the lease of a 33,000-sq. ft site to establish a process development laboratory in King of Prussia, Pennsylvania.

"We are excited to announce our third site in the US and proud to become a member of the New Jersey community. Cranbury is a growing hub for the biotech and biopharma industries, and we look forward to working with and serving our partners in the area to benefit patients worldwide," said Dr Chris Chen, CEO of WuXi Biologics.

Read More

Related news

Rentschler Biopharma and Vetter team up to simplify processes

Rentschler Biopharma and Vetter team up to simplify processes

6 Jul 2020

Companies agree that the key to tackling drug development complexity is collaboration.

Read more 
iNova Pharmaceuticals announces the launch of iPitch 2020

iNova Pharmaceuticals announces the launch of iPitch 2020

3 Jul 2020

Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.

Read more 
Ajinomoto introduces fast track platform for drug product manufacturing

Ajinomoto introduces fast track platform for drug product manufacturing

30 Jun 2020

AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.

Read more 
Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

29 Jun 2020

The company agrees to provide CEPI with 100 million glass vials, which can store 20 doses per vial (2 billion doses in total).

Read more 
PCI Pharma Services completes biotech Center of Excellence

PCI Pharma Services completes biotech Center of Excellence

29 Jun 2020

The global outsourcing solutions provider is also set to expand its biotech capabilities in Europe.

Read more 
CordenPharma & Moderna extend lipid supply agreement for Moderna’s coronavirus vaccine

CordenPharma & Moderna extend lipid supply agreement for Moderna’s coronavirus vaccine

23 Jun 2020

The amended manufacturing agreement, which originally specified CordenPharma facilities Switzerland, now extends to the CDMOs France and US sites.

Read more 
FDA approves new Dupixent prefilled pen

FDA approves new Dupixent prefilled pen

23 Jun 2020

The prefilled pen supports more convenient self-administration for patients with chronic type 2 inflammatory diseases.

Read more 
Sanofi to build EUR 490 million vaccine production facility in France

Sanofi to build EUR 490 million vaccine production facility in France

16 Jun 2020

The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccines

Read more 
BIA Separations introduces PrimaS multi-mode ligand bioprocessing technology

BIA Separations introduces PrimaS multi-mode ligand bioprocessing technology

16 Jun 2020

Novel platform initially focussed on high-resolution industrial-scale processing of therapeutic mRNA.

Read more 
Catalent inks deal with AstraZeneca to manufacture COVID-19 vaccine candidate

Catalent inks deal with AstraZeneca to manufacture COVID-19 vaccine candidate

15 Jun 2020

The company's Anagni, Italy facility will prepare to supply hundreds of millions of doses of the vaccine candidate if it's approved.

Read more